Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicals[1]
- Market Cap ₹ 13.2 Cr.
- Current Price ₹ 35.3
- High / Low ₹ 47.8 / 24.2
- Stock P/E
- Book Value ₹ 0.27
- Dividend Yield 0.00 %
- ROCE -58.4 %
- ROE -193 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 132 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.62% over past five years.
- Promoter holding is low: 30.8%
- Company has a low return on equity of -38.6% over last 3 years.
- Debtor days have increased from 29.5 to 60.1 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.40 | 11.05 | 17.48 | |
0.03 | 0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.12 | 14.42 | 19.69 | |
Operating Profit | -0.03 | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.28 | -3.37 | -2.21 |
OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.81% | -30.50% | -12.64% | |||||
0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.05 | 0.04 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.40 | 0.62 | 0.61 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.69 |
Profit before tax | -0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -4.47 |
Tax % | 0.00% | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | 1.59% | ||
-0.03 | 0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -5.75 | -4.56 | |
EPS in Rs | -0.08 | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -15.37 | -12.19 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -25% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -15300% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | -8% |
1 Year: | 26% |
Return on Equity | |
---|---|
10 Years: | -9% |
5 Years: | -18% |
3 Years: | -39% |
Last Year: | -193% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.90 | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Reserves | 0.06 | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -4.35 |
0.90 | 0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | |
0.08 | 0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | |
Total Liabilities | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 |
2.53 | 2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.28 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 |
2.41 | 2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.95 | |
Total Assets | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.20 | |
0.00 | 0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | -1.59 | |
0.03 | 0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | 1.43 | |
Net Cash Flow | 0.00 | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 | -0.36 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.69 | 60.12 | |||||
Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | 123.74 | |||||
Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | 382.60 | |||||
Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | -198.75 | |||||
Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.28 | |||||
ROCE % | -0.62% | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.94% | -58.35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Aug - Appointed Mr. SAMSAD ALAM KHAN, Practicing Company Secretary as a Secretarial Auditor of the company for FY 2024-25.
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Aug - Appointed M/S B A SHAH & ASSOCIATES, Chartered Accountants as an Internal Auditor of the Company for FY 2024-25.
- Financial Results For Quarter Ended On 30/06/2024 14 Aug
- Board Meeting Outcome for OUTCOME OF BOARD MEETING 14 Aug
- Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Regulation 29 Read With Regulation 33 Of SEBI (LODR) Regulations, 2015. 6 Aug
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the formulation of Tablets, Ointments,
Capsules, and Injectables.